Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200 Day Moving Average – Here’s What Happened

Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $34.41 and traded as high as $42.44. Global X Genomics & Biotechnology ETF shares last traded at $42.37, with a volume of 15,989 shares.

Global X Genomics & Biotechnology ETF Stock Up 3.2%

The stock has a market capitalization of $51.69 million, a PE ratio of -18.11 and a beta of 1.03. The business’s fifty day moving average is $37.87 and its two-hundred day moving average is $34.41.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several hedge funds have recently modified their holdings of GNOM. Creative Financial Designs Inc. ADV purchased a new stake in Global X Genomics & Biotechnology ETF in the first quarter valued at about $95,000. Halbert Hargrove Global Advisors LLC raised its stake in Global X Genomics & Biotechnology ETF by 182.4% in the 2nd quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock worth $115,000 after acquiring an additional 8,839 shares during the last quarter. HighTower Advisors LLC raised its position in Global X Genomics & Biotechnology ETF by 16.7% during the 1st quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after buying an additional 2,184 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 18.5% during the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock worth $125,000 after purchasing an additional 2,329 shares during the last quarter. Finally, Oxinas Partners Wealth Management LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 12.1% during the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after purchasing an additional 1,751 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.